Clinical trials: Non-hodgkin Lymphoma
Diffuse Large B Cell Lymphoma, Follicular Lymphoma
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
Evaluation of the efficacy and safety of CD22-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of recurrent or refractory CD22 positive B cell acute lymphoblastic leukemia (B-ALL)
- Conditions
- Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Primary Cutaneous Follicle Centre Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Trial name
- NCT03999697
- Testing
- Autologous chimeric antigen receptor T cell transfusing agent targeting CD22
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment.
- Trial name
- NCT04047797
- Testing
- Ixazomib, Ixazomib Citrate, Rituximab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Mild and Moderate Oligozoospermia Asthenospermia or Oligoasthenospermia and the Syndrome Differentiation Type is Shen (Kidney) Essence Deficiency
Effectiveness and Safety of Guilu Erxian Oral Liquid in the Treatment of Oligozoospermia and Asthenospermia With Syndrome of Shen (Kidney) Essence Deficiency
The main function of Guilu Erxian Oral Liquid is to warm the shen (kindney) and replenish essence. It is used for chronic shen (kindney) deficiency, waist and knee weakness, spermatorrhea and impotence.
- Trial name
- NCT07270146
- Testing
- Guilu Erxian Oral Liquid, Wuzi Yanzong oral liquid
- Where
- China
- Volunteers
- 360 people
- Sponsor
- DongE E Jiao Coporation Limited
Diffuse Large B-cell Lymphoma
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study aimed to evaluate the efficacy of a novel regimen consisting of polatuzumab vedotin in combination with rituximab, gemcitabine, dexamethasone, and cisplatin (PV-RGDP) for the treatment of diffuse large B-cell lymphoma…
- Trial name
- NCT05498220
- Testing
- Polatuzumab vedotin (PV), Rituximab, Hyaluronidase
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
ALL, B Cell Lymphoma
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Background: Although progress has been made in treating children with B-cell cancers such as leukemia or lymphoma, many children do not respond to the standard treatments.
- Conditions
- ALL, B Cell Lymphoma, Leukemia, Large Cell Lymphoma
- Trial name
- NCT01593696
- Testing
- Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Childhood Lymphoma
Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
Toxicities related to pediatric cancer treatment can lead to significant illness, organ damage, treatment delays, increased health care cost, and decrease in quality of life.
- Conditions
- Lymphoma, Childhood Lymphoma, Solid Tumor, Childhood Solid Tumor
- Trial name
- UVA-Gen001 (NCT02624388)
- Testing
- Genistein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Virginia
Non-hodgkin Lymphoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find…
- Trial name
- NCT05998642
- Testing
- Methotrexate, Rituximab (where available), Ibrutinib
- Where
- 8 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Dementia, Dementia, Vascular
Feasibility of the SmartPrompt for Improving Everyday Function in Dementia
Difficulty completing everyday tasks is a primary reason for the high cost of care, loss of caregiver paid hours, and general caregiver burden associated with dementia.
- Conditions
- Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mixed
- Trial name
- SmartPrompt (NCT04313582)
- Testing
- SmartPrompt smartphone application
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Temple University
B-cell Lymphoma
Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
This is an open label, multicenter, dose escalation, phase Ib study to determine the recommended dose by assessing the maximum tolerated dose (MTD), safety and efficacy of ibrutinib in combination with R-DHAP (Group A/Abis) or…
- Trial name
- BIBLOS (NCT02055924)
- Testing
- Ibrutinib and immunochemotherapies
- Where
- 15 sites in Belgium, France
- Volunteers
- 85 people
- Sponsor
- The Lymphoma Academic Research Organisation
Non Hodgkin´s Lymphomas, Hodgkin´s Lymphomas
Music & Cancer - Live Music During Chemotherapy
Main purpose: To determine if live music moderates the level of chemotherapy related anxiety, in patients with haematological cancer The investigators hypothesize that live music: 1.
- Trial name
- NCT01870479
- Testing
- Live music, Taped music
- Where
- 7 sites in Denmark
- Volunteers
- 143 people
- Sponsor
- Margrethe Langer Bro
Hepatic Insufficiency, Liver Diseases
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.
- Trial name
- NCT07559474
- Testing
- INCB123667
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice
The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell…
- Trial name
- FIRE (NCT03425591)
- Testing
- Ibrutinib
- Where
- France
- Volunteers
- 508 people
- Sponsor
- Janssen-Cilag Ltd.
Solid Tumors, Lymphoma, Non-Hodgkin
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Part 1 and Part 2 of this trial will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered every 3 weeks as a 2 hour intravenous (IV) infusion (Part 1), and as an…
- Conditions
- Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT00871910
- Testing
- SCH 727965, Aprepitant, Ondansetron
- Volunteers
- 81 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma
Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's…
- Trial name
- NCT00003924
- Testing
- recombinant interferon alfa
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
Diffuse Large B Cell Lymphoma
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
The proposed study is a prospective, single-center and open-ended study in patients over the age of 70 with treatment-naive diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05809180
- Testing
- Rituximab, Orelabrutinib, Pomalidomide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Non-hodgkin Lymphoma,B Cell
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy
This is a single arm, open-label, phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T, an autologous tri-functional anti- CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in Refractory/ Relapsed CD19…
- Trial name
- NCT03720496
- Testing
- CD19-TriCAR-T
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Timmune Biotech Inc.
Non Hodgkin's Lymphoma
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
The main treatments for non-Hodgkin's lymphoma are surgery, radiotherapy, chemotherapy, and bone marrow transplantation. Neutropenia is the most common and serious complication of most chemotherapy.
- Trial name
- NCT04497688
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 104 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients with peripheral T-cell…
- Trial name
- NCT07293403
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood…
- Trial name
- Aquarius (NCT07154823)
- Testing
- None - Observational Study
- Where
- 13 sites in United States
- Volunteers
- 550 people
- Sponsor
- Tempus AI
Cutaneous T Cell Lymphoma
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Investigators plan to perform a pilot study that aims to characterize the microbiome of human cutaneous T cell lymphoma patients and compare this to the microbiome of age and sex matched controls.
- Trial name
- NCT03932279
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.